Clinical Scorecard: Beacon Reports Interim Data on XLRP Therapy

At a Glance

Key Highlights

• 6-month interim data from phase 2 DAWN trial showed promising improvements in visual function
• Laru-zova gene therapy was generally well-tolerated with favorable safety profile
• DAWN study evaluates two dose levels in untreated eye of patients previously treated for XLRP

Guideline-Based Recommendations

Diagnosis

• Diagnosis of XLRP confirmed by genetic testing identifying RPGR mutations

Management

• Consider enrollment in clinical trials evaluating laru-zova gene therapy for eligible XLRP patients
• Monitor for safety and efficacy outcomes post-gene therapy administration

Monitoring & Follow-up

• Regular ophthalmic assessments to evaluate visual function improvements and adverse events
• Follow-up beyond 6 months to assess long-term safety and efficacy

Risks

• Potential risks associated with gene therapy vectors and immune responses require monitoring
• Safety profile to be further defined in ongoing pivotal trials

Patient & Prescribing Data

XLRP patients previously treated with RPGR-targeted gene therapy and treatment-naïve patients

Laru-zova shows promise as a best-in-class gene therapy with codon-optimized full-length RPGR gene and high photoreceptor transduction

Clinical Best Practices

• Use well-established AAV vector with proprietary capsid for efficient photoreceptor targeting
• Evaluate both safety and efficacy at multiple dose levels in clinical trials
• Enroll patients in ongoing pivotal phase 2/3 VISTA trial to further define therapeutic benefit

References

• Beacon Therapeutics Press Release on DAWN Trial Interim Data
• ARVO 2025 Annual Meeting Abstracts